1. Cochrane L, Brumpton K, Winter S, Bell K, Burnham H, Wadwell K, et al. Prevalence and outcomes of overweight and obesity among pregnant women in rural Queensland. Aust J Rural Health. 2019;27(2):164-9. PMID: 30950131 DOI: 10.1111/ajr.12495
2. Lockwood G, Ledger W, Barlow D, Groome N, Muttukrishna S. Measurement of inhibin and activin in early human pregnancy: demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome. Biol Reprod. 1997;57(6):1490-4. PMID: 9408259 DOI: 10.1095/biolreprod57.6.1490
3. Mizejewski GJ. Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. Exp Biol Med. 2007;232(8):993-1004. PMID: 17720945 DOI: 10.3181/0612-MR-291
4. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem. 1997;272(21):13835-42. PMID: 9153241 DOI: 10.1074/jbc.272.21.13835
5. de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update. 2002;8(6):529-41. PMID: 12498423 DOI: 10.1093/humupd/8.6.529
6. Gagnon A, Wilson RD. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918-32. PMID: 19038077 DOI: 10.1016/S1701-2163(16)32973-5
7. Jelliffe-Pawlowski LL, Shaw GM, Currier RJ, Stevenson DK, Baer RJ, O'Brodovich HM, et al. Association of early-preterm birth with abnormal levels of routinely collected first-and second-trimester biomarkers. Am J Obstet Gynecol. 2013;208(6):492.e1-11. PMID: 23395922 DOI: 10.1016/j.ajog.2013.02.012
8. Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:194-201. PMID: 25305662 DOI: 10.1016/j.ejogrb.2014.09.027
9. Broumand F, Lak SS, Nemati F, Mazidi A. A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women. Electron Physician. 2018;10(1):6186-92. PMID: 29588818 DOI: 10.19082/6186
10. Singnoi W, Wanapirak C, Sekararithi R, Tongsong T. A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study. BMC Pregnancy Childbirth. 2019;19(1):124. PMID: 30971214 DOI: 10.1186/s12884-019-2266-y
11. Lentz EJ, Park AL, Langlois AW, Huang T, Meschino WS, Ray JG. Risk of severe maternal morbidity or death in relation to prenatal biochemical screening: population-based cohort study. Am J Perinatol. 2019;14:333. PMID: 31412403 DOI: 10.1055/s-0039-1694731
12. Lambert-Messerlian GM, Silver HM, Petraglia F, Luisi S, Pezzani I, Maybruck WM, et al. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancy. J Soc Gynecol Investig. 2000;7(3):170-4. PMID: 10865185 DOI: 10.1016/s1071-5576(00)00050-2
13. Muttukrishna S, Hyett J, Paine M, Moodley J, Groome N, Rodeck C. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol (Oxf). 2006;64(4):469-73. PMID: 16584522 DOI: 10.1111/j.1365-2265.2006.02476.x
14. Silver HM, Lambert-Messerlian GM, Reis FM, Diblasio AM, Petraglia F, Canick JA. Mechanism of increased maternal serum total activin a and inhibin a in preeclampsia. J Soc Gynecol Investig. 2002;9(5):308-12. PMID: 12383916 DOI: 10.1016/s1071-5576(02)00165-x
15. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-99. PMID: 15733721 DOI: 10.1016/S0140-6736(05)17987-2
16. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44. PMID: 20598363 DOI: 10.1016/S0140-6736(10)60279-6
17. Fitzgerald B, Levytska K, Kingdom J, Walker M, Baczyk D, Keating S. Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta. 2011;32(4):339-45. PMID: 21388678 DOI: 10.1016/j.placenta.2011.01.018